

GTGGCTGTAACTTACGTGTACTTTACCAACGAGCTGAAGCAGATGCAGGACAAGTACTCCAAAAGTGGCATTGCTTGTTTCTTAAAAGAA ValAlaValThrTyrValTyrPheThrAsnGluLeuLysGlnMetGlnAspLysTyrSerLysSerGlyIleAlaCysPheLeuLysGlu TTTCCTCACTGACTATAAAAGAATAGAAGGAAGGGCTTCAGTGACCGGCTGCCTGGCTGACTTACAGCAGTCAGACTCTGACAGGATC 181

GATGACAGTTATTGGGACCCCAATGACGAAGAGAGTATGAACAGCCCCTGCTGGCAAGTCAAGTGGCAACTCCGTCAGCTCGTTAGAAAG AspAspSerTyrTrpAspProAsnAspGluGluSerMetAsnSerProCysTrpGlnValLysTrpGlnLeuArgGlnLeuValArgLys

ATGATTTTGAGAACCTCTGAGGAAACCATTTCTACAGTTCAAGAAAAGCAACAAAATATTTCTCCCCTAGTGAGAGAAAGAGGTCCNCAG MetIleLeuArgThrSerGluGluThrIleSerThrValGlnGluLysGlnGln**Asn**IleSerProLeuValArgGluArgGlyProGln 361

AGAGTAGCAGCTCACATAACTGGGACCAGAGGAAGAAGCAACACATTGTCTTCTCCAAAACTCCAAGAATGAAAAGGCTCTGGGCCGCAAA ArgValAlaAlaHisIleThrGlyThrArgGlyArgSerAsnThrLeuSerSerProAsnSerLysAsnGluLysAlaLeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgLysAlaCeuGlyArgCeuGlyA451 121

ATAAACTCCTGGGAATCATCAAGGAGTGGGCATTCATTCCTGAGCAACTTGCACTTGAGGAATGGTGAACTGGTCATCCATGAAAAAGGG IleAsnSerTrpGluSerSerArgSerGlyHisSerPheLeuSerAsnLeuHisLeuArgAsnGlyGluLeuValIleHisGluLysGly 541 51

PheTyrTyrIleTyrSerGlnThrTyrPheArgPheGlnGluGluIleLysGluAsnThrLysAsnAspLysGlnMetValGlnTyrIle ttttactacatctattcccaaacatactttcgatttcaggaggaaataaaagaaaacacaaaaggaacgacaaatggtccaatatatt 631 81

TACAAATACACAAGTTATCCTGACCCTATATTGTTGATGAAAAGTGCTAGAAATAGTTGTTGGTCTAAAGATGCAGAATATGGACTCTAT Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro I le Leu Leu Met Lys Ser Ala Arg Asn Ser Cys Trp Ser Lys Asp Ala Glu Tyr Gly Leu Tyr 721 211

TCCATCTATCAAGGGGGAATATTTGAGCTTAAGGAAAATGACAGAATTTTTGTTTCTGTAACAAATGAGCACTTGATAGACATGGACCAT SerIleTyrGlnGlyGlyIlePheGluLeuLysGluAsnAspArgIlePheValSerValThrAsnGluHisLeuIleAspMetAspHis 811 241

GluAlaSerPhePheGlyAlaPheLeuValGlyStp 901

FIG._ 1



Avi Ashkenazi et al.
U.S.S.N. 09/603,866
N. ds for Making Apo-2 Ligand Using Divalent al lons
Sheet 2 of 12




FIG._2A

Avi Ashkenazi et al. U.S.S.N. 09/603,866 Mc — Js for Making Apo-2 Ligand Using Divalent Sheet 3 of 12

l Ions

3 / 12



IG._2B



Crystallographic Data

	Apo-2L (114-281)	Apo-2L (91-281) D218A	Apo-2L (91-281) D218A
Crystal			
Space Group	P6 ₃	R32	R32
Unit Cell (Å)	a=72.5 c=140	a=66.4 c=197.6	a=66.4 c=197.7
Resolution (Å)	3.9	1.9	1.3
Coverage (%)	94 (96)	93 (99)	100 (100)
<i σ(i)=""></i>	5.9	10.1	12.4
# Unique (hkl)	3589	12680	41840
Redundancy	4.9	4.3	12.1
R _{symm} (%)	15.4 (34)	6.2 (27)	6.4 (34)
# Protomers in ASU	2	1	1
Refinement			
R _{cryst} (%)	33.8	20	
R _{free} (%)	27.6	22	
rmsd Bonds (Å)	0.009	0.015	0.007
rmsd Angles (°)	1.79	2.0	1.41
Average B-Values		14	14
# Water Molecules	0	170	


Rsymm = $\Sigma_{\pmb{h}}\Sigma_{\pmb{i}}(I_{\pmb{h}\pmb{i}}^- < I_{\pmb{h}}^>)/\Sigma_{\pmb{h}}\mathbf{I}$ where I_h is the mean structure factor intensity of i observations of symmetry-related reflections with Bragg index \pmb{h} . $R_{\text{Cryst}} = \Sigma_{\pmb{h}}\Sigma_{\pmb{i}}|IF_{\text{Obs}}|-IF_{\text{Calc}}|I|/\Sigma_{\text{IFObs}}|$ where F_{Obs} and F_{Calc} are the observed and calculated structure factor amplitudes. $R_{\text{free}} = \Sigma_{(hkl)} \varepsilon \tau^{|I|} F_{\text{Obs}}(hkl)^{|I|} F_{(hkl)}^{|I|} F_$


FIG._2C



0

	A				A '	B'
	121	130	140	150	160	170
Apo2L TNF- β TNF- α CD40L FasL RANKL	KPAAHLIGI KPVAHVVAN QIAAHVISE RKVAHLTGE) V E	P	SKQNSLLWR? QAEGQLQWLI KTTSVLQWAI SRSMPLEWE!	SSRSGHSFLSN ANTDRAFLQDG NRRANALLANG EKGYYTMSNNI DTY.GIVLLSG HDR.GWAKISN	FSLS VELR VTLE VKYK
	в с		_	D		
	→	180	190	200	210	•
Apo2L TNF- β TNF- α CD40L FasL RANKL	NN.SLLVPT DN.QLVVPS NGKQLTVKF KG.GLVINE	rsgiyfvysg seglyliysg Roglyyiyag rtglyfvysk	VVFSGKAY VLFKGQG. VTFCS VYFRGQ	SPKATSSPLYCPSTHVINREAS;SCNNLI	QMVQYIYKYTS YLAHEVQLFSS LLTHTISRIAV SQAPFIASLCI PLSHKVYMRNS QLMVYVTKTSI	QYPF SYQT KSPG KYPQ
	E			F	G	
	220	230		240	250	260
Apo2L TNF- β TNF- α CD40L FasL RANKL	220 PILLMKSAF HVPLLSSQF KVNLLSAIF RFERILLRA	RNSCWSKDAE KMVYPGLQE. KSPCQRETPE AANTHSSAKP IMSYCTTGQ.	YGL PWL GAEAKPWY CGQ	YSIYQGGIFI HSMYHGAAF(EPIYLGGVF) QSIHLGGVFI RSSYLGAVFI	250 ELKENDRIFVS QLTQGDQLSTH QLEKGDRLSAF ELQPGASVFVN NLTSADHLYVN KLRSGEEISIE	VTNE TDGI INRP VTDP
TNF- β TNF- α CD40L FasL	220 PILLMKSAF HVPLLSSQF KVNLLSAIF RFERILLRA	RNSCWSKDAE KMVYPGLQE. KSPCQRETPE AANTHSSAKP IMSYCTTGQ.	YGL PWL GAEAKPWY CGQ	YSIYQGGIFI HSMYHGAAF(EPIYLGGVF) QSIHLGGVFI RSSYLGAVFI	ELKENDRIFVS QLTQGDQLSTH QLEKGDRLSAE ELQPGASVFVN NLTSADHLYVN	VTNE TDGI INRP VTDP







Avi Ashkenazi et al.
U.S.S.N. 09/603,866
Me. _is for Making Apo-2 Ligand Using Divalent ' 1 Ions
Sheet 7 of 12





FIG._5



Effect of ZnSO4 Additions On Apo2L Product Accumulation

60

Temperature (°C)

70

80

90

100

50


230


FIG._7


20


30

40












FIG._12

